Related Experiment Video
Updated: Jul 15, 2025
06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
10.7K
Second-Line Pharmaceutical Treatments for Patients with Type 2 Diabetes.
Rohit Vashisht1, Ayan Patel1,2, Lisa Dahm2
1Bakar Computational Health Sciences Institute, University of California, San Francisco.
JAMA Network Open
|October 2, 2023
Summary
New diabetes treatments added to metformin, including SGLT2 inhibitors and GLP-1 receptor agonists, improve glycemic control and reduce complications. These findings support using real-world data to guide type 2 diabetes treatment decisions.
Area of Science:
- Endocrinology
- Pharmacology
- Real-world evidence studies
Background:
- Metformin monotherapy is often insufficient for managing type 2 diabetes.
- Assessing the comparative effectiveness and safety of add-on treatments is crucial for optimizing patient care.
Purpose of the Study:
- To evaluate the comparative effectiveness and safety of four common add-on therapies to metformin: sulfonylurea, DPP4 inhibitors, SGLT2 inhibitors, and GLP-1 receptor agonists.
- To determine the feasibility of using electronic health record data for such comparative effectiveness research.
Main Methods:
- A retrospective cohort study using electronic health records from the University of California Health system.
- Multidimensional propensity score matching and leave-one-medical-center-out sensitivity analysis were employed.
- New users of add-on therapies were followed for up to 5 years to assess time to metabolic failure (HbA1c ≥7.0%) and incidence of adverse outcomes.
Main Results:
- Sodium-glucose cotransporter-2 inhibitors (SGLT2I), dipeptidyl peptidase-4 inhibitors (DPP4I), and glucagon-like peptide-1 receptor agonists (GLP1RA) were more effective than sulfonylureas in maintaining glycemic control.
- SGLT2I and GLP1RA use was associated with reduced risk of chronic kidney disease and kidney failure compared to sulfonylureas.
- DPP4I and SGLT2I use showed fewer cardiovascular events than sulfonylureas, and SGLT2I use was linked to lower rates of hepatic dysfunction.
Conclusions:
- Add-on therapies like SGLT2 inhibitors and GLP-1 receptor agonists demonstrate significant benefits in glycemic control and reducing diabetes-related complications.
- Real-world data analytics can rapidly generate evidence to inform clinical decision-making for type 2 diabetes management.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
223
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
223
01:24Glucagon-like Receptor Agonists
348
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
348
01:15Diabetes: Management and Pharmacotherapy
302
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
302
01:06Oral Hypoglycemic Agents: Glinides
176
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
176
01:22Diabetes Mellitus: Type 2 and Gestational
2.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.5K
01:23Dipeptidyl Peptidase 4 Inhibitors
204
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
204